| scholarly article | Q13442814 |
| P50 | author | Timothy J Wilt | Q107974776 |
| P2093 | author name string | Malcolm D Mason | |
| Anne Cleves | |||
| Gabriel Jones | |||
| Howard G Kynaston | |||
| Mike D Shelley | |||
| P2860 | cites work | Cancer statistics, 2007 | Q29547293 |
| A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. | Q31944288 | ||
| Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder | Q33368290 | ||
| Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. | Q35685707 | ||
| Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer | Q36590798 | ||
| Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study | Q36610731 | ||
| Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses | Q37676425 | ||
| Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma | Q37896172 | ||
| Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study | Q40496147 | ||
| Pharmacokinetic study to optimize the intravesical administration of gemcitabine. | Q42999414 | ||
| Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study | Q43154954 | ||
| Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial | Q43159409 | ||
| Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial | Q43254447 | ||
| Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance | Q43258593 | ||
| Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer | Q43272926 | ||
| Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study | Q44315406 | ||
| Intravesical gemcitabine: a phase 1 and pharmacokinetic study | Q44735433 | ||
| Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study | Q44887089 | ||
| Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). | Q45014818 | ||
| Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. | Q45236378 | ||
| Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. | Q45949960 | ||
| Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience | Q46682002 | ||
| Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. | Q46835350 | ||
| P433 | issue | 4 | |
| P921 | main subject | bladder cancer | Q504775 |
| P304 | page(s) | 496-505 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review | |
| P478 | volume | 109 |
| Q64927304 | Advances in risk stratification of bladder cancer to guide personalized medicine. |
| Q37660290 | Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. |
| Q91401510 | Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now? |
| Q38807180 | Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review |
| Q94686361 | Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer |
| Q53124991 | Current clinical trials in non-muscle invasive bladder cancer. |
| Q38129947 | Current intravesical therapy for non-muscle invasive bladder cancer |
| Q38156190 | Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer |
| Q41860499 | Gemcitabine and Chlorotoxin Conjugated Iron Oxide Nanoparticles for Glioblastoma Therapy |
| Q46075170 | Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity. |
| Q41434863 | Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer |
| Q38063552 | Intravesical therapies for bladder cancer - indications and limitations. |
| Q38260521 | Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis of the published results of randomized clinical trials |
| Q37053829 | Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? |
| Q38728936 | Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin |
| Q33561637 | Natural biology and management of nonmuscle invasive bladder cancer |
| Q86507875 | Perioperative chemotherapy: when to use it, what to use, and why |
| Q26752368 | Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective |
| Q91878251 | Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients |
| Q34552725 | Recent advances in the diagnosis and treatment of bladder cancer. |
| Q38286242 | Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs |
| Q37564451 | Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs |
| Q58795653 | The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis |
| Q43523233 | The quality of life in patients during intravesical treatment and correlation with local symptoms |
| Q84197391 | [Non-muscle invasive transitional cell carcinoma of the bladder. New developments in diagnostics and therapy] |
Search more.